These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

696 related articles for article (PubMed ID: 6426835)

  • 1. Transfusion support for haemophiliacs.
    Allain JP
    Clin Haematol; 1984 Feb; 13(1):99-117. PubMed ID: 6426835
    [No Abstract]   [Full Text] [Related]  

  • 2. The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia.
    McMillan CW; Greene WB; Blatt PM; White GC; Roberts HR
    Instr Course Lect; 1983; 32():210-6. PubMed ID: 6443730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of hemophiliacs with inhibitors].
    Fujimaki M
    Rinsho Ketsueki; 1985 Jul; 26(7):1059-68. PubMed ID: 3932719
    [No Abstract]   [Full Text] [Related]  

  • 4. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
    Schimpf K; Schwarz P; Kunschak M
    Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
    [No Abstract]   [Full Text] [Related]  

  • 5. Approaches to plasma fractionation for improved recovery and the development of potentially useful clinical factors.
    Johnson AJ; Mathews RW; Fulton AJ
    Clin Haematol; 1984 Feb; 13(1):3-15. PubMed ID: 6426834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New alternatives and strategies in the treatment of inhibitors.
    Hoyer LW
    Prog Clin Biol Res; 1984; 150():367-72. PubMed ID: 6431440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advances in the field of hemophilia therapy].
    Loeliger EA; Veltkamp JJ
    Ned Tijdschr Geneeskd; 1968 Sep; 112(36):1593-5. PubMed ID: 5680135
    [No Abstract]   [Full Text] [Related]  

  • 8. Current concepts in diagnosis and management of hemophilia.
    Aledort LM
    Hosp Pract (Off Ed); 1982 Oct; 17(10):77-84, 89-92. PubMed ID: 6811410
    [No Abstract]   [Full Text] [Related]  

  • 9. [Therapy-induced hepatitis risk in hemophilia patients].
    Schiller WG; Renger FG
    Z Arztl Fortbild (Jena); 1983; 77(19):807-10. PubMed ID: 6417919
    [No Abstract]   [Full Text] [Related]  

  • 10. [Secondary effects of transfusions in hemophiliacs].
    Allain JP
    Rev Fr Transfus Immunohematol; 1979 Feb; 22(1):77-81. PubMed ID: 493793
    [No Abstract]   [Full Text] [Related]  

  • 11. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
    Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
    Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
    [No Abstract]   [Full Text] [Related]  

  • 12. Key issues in inhibitor management in patients with haemophilia.
    Gomez K; Klamroth R; Mahlangu J; Mancuso ME; Mingot ME; Ozelo MC
    Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s319-29. PubMed ID: 24333092
    [No Abstract]   [Full Text] [Related]  

  • 13. [Substitution therapy of hemorrhagic diseases].
    Haupt H
    Anasthesiol Intensivmed Prax; 1975 Oct; 11(1):137-44. PubMed ID: 1225069
    [No Abstract]   [Full Text] [Related]  

  • 14. Substitution treatment of hemophilia a and b.
    Duckert F
    Schweiz Med Wochenschr; 1975 Jun; 105(24):783-4. PubMed ID: 1145162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies.
    Engelfriet CP; Reesink HW; Mannucci PM; Gringeri A; Ingerslev J; Brettler DB; Mauser-Bunschoten EP; Negrier C; Berntorp E; Smith OP; Shapiro AD
    Vox Sang; 2000; 78(4):256-61. PubMed ID: 10970234
    [No Abstract]   [Full Text] [Related]  

  • 16. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
    Nilsson IM; Berntorp E
    Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694
    [No Abstract]   [Full Text] [Related]  

  • 17. The management of hemophilia patients with inhibitors.
    Nilsson IM
    Transfus Med Rev; 1992 Oct; 6(4):285-93. PubMed ID: 1421831
    [No Abstract]   [Full Text] [Related]  

  • 18. [Transfusion therapy of hemophilia A and B].
    Egli H
    Bibl Haematol; 1967; 27():204-10. PubMed ID: 5595089
    [No Abstract]   [Full Text] [Related]  

  • 19. T-lymphocyte subpopulations in patients with classic hemophilia treated with cryoprecipitate and lyophilized concentrates.
    Menitove JE; Aster RH; Casper JT; Lauer SJ; Gottschall JL; Williams JE; Gill JC; Wheeler DV; Piaskowski V; Kirchner P; Montgomery RR
    N Engl J Med; 1983 Jan; 308(2):83-6. PubMed ID: 6401196
    [No Abstract]   [Full Text] [Related]  

  • 20. HTLV-I antibody status in hemophilia patients treated with factor concentrates prepared from U.S. plasma sources and in hemophilia patients with AIDS.
    Chorba TL; Jason JM; Ramsey RB; Lechner K; Pabinger-Fasching I; Kalyanaraman VS; McDougal JS; Cabradilla CD; Tregillus LC; Lawrence DN
    Thromb Haemost; 1985 Apr; 53(2):180-2. PubMed ID: 2992112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.